Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -52.59% is 523% below its 5-year average of -8.44%, around the middle of its 5-year range (-80.82%–2.62%).
65.21% below its 12-month average of -31.83%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-03-31): -8.66%.
NET PROFIT MARGIN
-52.59%
NET PROFIT MARGIN AVG TTM
-31.83%
NET PROFIT MARGIN AVG 3Y
-13.27%
NET PROFIT MARGIN AVG 5Y
-8.44%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-65.21%
CURRENT VS 3Y AVG
-296.34%
CURRENT VS 5Y AVG
-522.82%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 452 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
BGM Group Ltd.
Market Cap
$118.63M
Net Profit Margin
-52.59%
TTM Avg
-31.83%
3Y Avg
-13.27%
5Y Avg
-8.44%
Market Cap
$118.50M
Net Profit Margin
-2955.63%
TTM Avg
-2231.78%
3Y Avg
-3480.44%
5Y Avg
-3216.57%
Market Cap
$119.09M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$118.02M
Net Profit Margin
-1030.42%
TTM Avg
-1409.68%
3Y Avg
-958.30%
5Y Avg
-801.33%
Market Cap
$117.43M
Net Profit Margin
-175.78%
TTM Avg
-311.79%
3Y Avg
-369.50%
5Y Avg
-4193.27%
Market Cap
$116.59M
Net Profit Margin
-422412.50%
TTM Avg
-387587.50%
3Y Avg
-197966.84%
5Y Avg
-131977.89%
Market Cap
$114.24M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$113.77M
Net Profit Margin
-270.22%
TTM Avg
-342.92%
3Y Avg
-204.73%
5Y Avg
-136.49%
Market Cap
$125.27M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BGM Group Ltd. (BGM) | $118.63M | -52.59% | -31.83% | -13.27% | -8.44% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $118.50M | -2955.63% | -2231.78% | -3480.44% | -3216.57% |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.09M | 0.00% | 0.00% | 0.00% | 0.00% |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | -1030.42% | -1409.68% | -958.30% | -801.33% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | -175.78% | -311.79% | -369.50% | -4193.27% |
| Genelux Corporation (GNLX)vs › | $116.59M | -422412.50% | -387587.50% | -197966.84% | -131977.89% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $114.24M | 0.00% | 0.00% | 0.00% | 0.00% |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | -270.22% | -342.92% | -204.73% | -136.49% |
| enGene Holdings Inc. (ENGN)vs › | $125.27M | 0.00% | 0.00% | 0.00% | 0.00% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | 31.95% | 15.97% | 7.99% | 5.33% |
Operating Margin
-33.2%
Net Profit Margin
-52.6%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-03-31 | -8.66% |
| 2025-09-30 | -80.82% |
| 2025-03-31 | -6.02% |
| 2024-09-30 | 0.00% |
| 2024-03-31 | 2.62% |
| 2023-09-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-09-30 | 0.00% |
